July 26, 2010 — The US Food and Drug Administration (FDA) has approved the first generic formulation of enoxaparin sodium injection (Sandoz, Inc; brand name, Lovenox; Sanofi-Aventis US, LLC), a ...

(RTTNews) - Sandoz, Inc., an unit of Novartis Pharma AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high ...

Zydus has signed a license and supply agreement with Chemi of Italy, a subsidiary of Italfarmaco Group, to launch the generic of Sanofi Aventis’s Lovenox (enoxaparin sodium injection) in seven dosage ...

Techdow USA Inc., a division of the Hepalink Group (Techdow USA), has announced its next finished drug product launch, Enoxaparin Sodium (Enoxaparin). This product is expected to launch in June of ...

Princeton, NJ, Sandoz Inc. (“Sandoz”) is initiating a recall of one lot (SAB06761A, Exp 04/2023) of Enoxaparin Sodium Injection, USP 40 mg/0.4 mL Single-Dose Syringes to the consumer level. A portion ...

Unlike unfractionated heparin (UFH), the low-molecular-weight heparin enoxaparin (Lovenox) is excreted mainly by the kidneys. To determine whether this characteristic heightens bleeding risk in ...

Emphasizing the tenet that antitrust laws are enacted to protect ­competition—and not competitors—the Third Circuit has rejected one competitor's claim that Sanofi-Aventis had an unfair advantage in ...

Watson Pharmaceuticals, Inc. confirmed that the United States District Court for the District of Massachusetts has granted a request by Momenta Pharmaceuticals, Inc. and Sandoz Inc. for a temporary ...

LONDON (Reuters) - Bayer AG has launched its new anticoagulant pill Xarelto in Britain and Germany, pricing the product on a par with Sanofi-Aventis's Lovenox injection, the company said on Thursday.

Enoxaparin (Lovenox) reduces the risk of blood clots in partially paralyzed stroke patients to a greater extent than unfractionated heparin, according to a large-scale multinational study. Researchers ...

NEW YORK/LONDON, Nov 6 (Reuters) - U.S. regulators have rejected Momenta Pharmaceuticals Inc's generic version of Sanofi-Aventis SA's top-selling thrombosis drug Lovenox, sending Momenta shares into a ...

Sandoz Canada launches its sixth biosimilar, an anticoagulant used to treat deep vein thrombosis, on the Canadian market. Sandoz Canada launched its sixth biosimilar, Inclunox (enoxaparin sodium), on ...